Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. Johann de Bono of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, U.K., and Professor Jeff Evans of the University of Glasgow, Scotland.

A total of 15 patients were enrolled in the trial. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and five patients had SD (stable disease) for 4-8 cycles, for a total disease control rate (CR (Complete response)+PR +SD) of 70%.

"The results to date using this treatment combination in late-stage cancer patients indicate that further studies using this drug combination are warranted," said Dr. Brad Thompson, President and CEO of Oncolytics. "We plan to initiate further studies in the U.S. using a modified dosage regime of REOLYSIN and the commonly used U.S. dosage of gemcitabine (800 mg/m(2)) in patients with advanced or metastatic pancreatic cancer in partnership with the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA)."

The U.K. trial (REO 009) is an open-label, dose-escalating, non-randomized study of REOLYSIN given intravenously with gemcitabine every three weeks. Gemcitabine (1000 mg/m(2)) was administered to patients in combination with escalating dosages of REOLYSIN intravenously.

Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours including pancreatic, l
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... (PRWEB) July 22, 2014 The next ... September 9th, 2014 and will comprise of the increasingly ... classes. The TechTrainings is a series of technical hands-on ... to help them reach the next step in their ... is taught by Jennifer Kang, Senior Statistician at ...
(Date:7/21/2014)... chemist in Syracuse University,s College of Arts and ... the synthesis of stainless nanoparticles. , Mathew M. ... a three-year, $360,000 grant from the National Science ... with metal stainless alloy nanostructures, the results of ... rechargeable lithium-ion batteries. , Maye,s approach ...
(Date:7/20/2014)... fuel gets recycled, the process releases radioactive krypton and ... with the related gas radon. A new porous material ... July 20 in Nature Materials shows how: ... not out. , The CC3 material could be ... nuclear fuel or air in buildings and also in ...
(Date:7/18/2014)... Researchers at the University of Illinois at Urbana-Champaign ... pillar-bowtie nanoantennas (pBNAs) can be used like traditional ... are much smaller than the wavelength of light ... red light). A standard optical microscope acts as ... film. , "Unlike conventional photographic film, the effect ...
Breaking Biology Technology:Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 3Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2A noble gas cage 2A noble gas cage 3'Nanocamera' takes pictures at distances smaller than light's own wavelength 2
... SHANGHAI, China, April 30 /Xinhua-PRNewswire/ -- Today, ... and NovaSecta in,their CRO Service Alliance CROSA ... companies. Tigermed,s expertise in clinical,development complements the ... the alliance., Sundia Meditech, United PharmaTech, ...
... add ... ... TSX symbol: SBS, CALGARY, April 30 /PRNewswire-FirstCall/ - Botaneco, a wholly-owned,subsidiary ... Croda Enterprise Technology, part of Croda,International Plc, an international manufacturer of speciality ingredients,with ...
... For-Profit Healthcare Companies, EL SEGUNDO, Calif., April ... care services, announced it has been honored for,the ... of the Top 125,ranking companies of employee-sponsored workforce ... that demonstrate a deep,commitment to learning and development ...
Cached Biology Technology:Shanghai CRO Service Alliance Adds Clinical Development Capabilities 2Shanghai CRO Service Alliance Adds Clinical Development Capabilities 3Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 2Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 3DaVita Honored for 4th Year as Training Top 125 Recipient 2
(Date:7/21/2014)... often results from the strength of immune response, rather ... rather than attacking the virus, might be a better ... the University of Washington, Seattle. She and her collaborators ... that for the H7N9 influenza, and their work has ... this highly virulent strain. The research is published ahead ...
(Date:7/21/2014)... Urban stormwater runoff is causing problems for the ... Environmental Protection Agency found stormwater runoff to be ... environments in rivers, streams, lakes, ponds, reservoirs, bays, ... can harm fish and wildlife populations, foul drinking ... from North Carolina State University are looking to ...
(Date:7/21/2014)... of life are now being developed to try and ... of species. Specifically, a recent model proposed by Petri ... accounts for species interactions with various degrees of symmetry, ... previous, simpler models, which apply random fitness levels to ... demonstrate that the resulting replicator ecosystems do not appear ...
Breaking Biology News(10 mins):Potential new flu drugs target immune response, not virus 2Filter bed substrates, plant types recommended for rain gardens 2Refined biological evolution model 2
... Data publishers should have the option of submitting their ... paper commissioned by the Global Biodiversity Information Facility (GBIF). ... recommendations made by Mark Costello and co-authors in the ... biodiversity data publication , freely available for download ...
... cells from patients with inherited heart muscle disease can ... to patients, including the possibility of testing new treatments ... cell model matches that of the clinical features of ... disease associated with sudden cardiac death Landmark study published ...
... more than 6,000 species of frogs in the world lay ... eggs out of water. This behavior protects the eggs from ... their risk of drying out. Justin Touchon, post-doctoral fellow at ... Panama may be altering frogs, course of evolution. By analyzing ...
Cached Biology News:Peer review option proposed for biodiversity data 2National Heart Centre Singapore develops world's first human heart cell model 2National Heart Centre Singapore develops world's first human heart cell model 3
MMP-1/8 (H-300)...
Gastric Carcinoma Marker [BY-1 (3H11)]...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: